Protagonist Therapeutics, Inc. (PTGX)

Market Cap	2.47B
Revenue (ttm)	323.80M
Net Income (ttm)	170.85M
Shares Out	59.60M
EPS (ttm)	2.68
PE Ratio	15.46
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,870,599
Open	39.01
Previous Close	39.54
Day's Range	38.91 - 41.68
52-Week Range	21.43 - 48.89
Beta	2.20
Analysts	Strong Buy
Price Target	54.63 (+31.67%)
Earnings Date	Nov 7, 2024

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an oral...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: PTGX
• Website: https://www.protagonist-inc.com

Financial Performance

In 2023, Protagonist Therapeutics's revenue was $60.00 million, an increase of 125.73% compared to the previous year's $26.58 million. Losses were -$78.96 million, -38.02% less than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price forecast is $54.63, which is an increase of 31.67% from the latest price.

Price Target

$54.63

(31.67% upside)

Analyst Consensus: Strong Buy